WNT pathway inhibitor pyrvinium pamoate inhibits the self-renewal and metastasis of breast cancer stem cells

International Journal of Oncology

Volumn 48, Issue 3, 2016, Pages 1175-1186

  Xu, Liang ^a   Zhang, Le ^a   Hu, Chun ^a   Liang, Shujing ^a   Fei, Xiaochun ^a   Yan, Ningning ^a   Zhang, Yanyun ^b   Zhang, Fengchun ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b Chinese Academy of Sciences   (China)

Author keywords

Breast cancer stem cells; Heterogeneity; Mammosphere; Pyrvinium pamoate; WNT pathway

Indexed keywords

ANTINEOPLASTIC AGENT; CD24 ANTIGEN; CLAUDIN; HERMES ANTIGEN; NERVE CELL ADHESION MOLECULE; OCTAMER TRANSCRIPTION FACTOR 4; PYRVINIUM EMBONATE; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR SOX2; VIMENTIN; CD44 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BREAST CANCER CELL LINE; BREAST METASTASIS; BULK DENSITY; CANCER COMBINATION CHEMOTHERAPY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CARCINOGENICITY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MCF 7 CELL LINE; MDA MB 231 CELL LINE; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCID MOUSE; SKBR3 CELL LINE; STEM CELL SELF-RENEWAL; TUMOR GROWTH; WNT SIGNALING PATHWAY; ANIMAL; BREAST TUMOR; CANCER STEM CELL; CANCER TRANSPLANTATION; CELL MOTION; CHEMISTRY; CYTOLOGY; EPITHELIAL MESENCHYMAL TRANSITION; EXPERIMENTAL MAMMARY NEOPLASM; MCF-7 CELL LINE; METABOLISM; METASTASIS; NONOBESE DIABETIC MOUSE; POLYMERASE CHAIN REACTION; TUMOR CELL LINE; TUMOR INVASION;

ANIMALS; ANTIGENS, CD24; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MCF-7 CELLS; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; POLYMERASE CHAIN REACTION; PYRVINIUM COMPOUNDS; WNT SIGNALING PATHWAY;

EID: 84958948834     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2016.3337     Document Type: Article

References (57)

1. Chiba T, Kita K, Zheng YW, Yokosuka O, Saisho H, Iwama A, Nakauchi H and Taniguchi H. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 44: 240-251, 2006
2. Ricardo S, Vieira AF, Gerhard R, Leitão D, Pinto R, Cameselle-Teijeiro JF, Milanezi F, Schmitt F and Paredes J. Breast cancer stem cell markers CD44, CD24 and ALDH1: Expression distribution within intrinsic molecular subtype. J Clin Pathol 64: 937-946, 2011
3. O'Brien CA, Kreso A and Jamieson CH. Cancer stem cells and self-renewal. Clin Cancer Res 16: 3113-3120, 2010
4. Lou H and Dean M. Targeted therapy for cancer stem cells: The patched pathway and ABC transporters. Oncogene 26: 1357-1360, 2007
5. Ishii H, Iwatsuki M, Ieta K, Ohta D, Haraguchi N, Mimori K and Mori M. Cancer stem cells and chemoradiation resistance. Cancer Sci 99: 1871-1877, 2008
6. Chuthapisith S, Eremin J, El-Sheemey M and Eremin O. Breast cancer chemoresistance: Emerging importance of cancer stem cells. Surg Oncol 19: 27-32, 2010
7. Saadin K and White IM. Breast cancer stem cell enrichment and isolation by mammosphere culture and its potential diagnostic applications. Expert Rev Mol Diagn 13: 49-60, 2013
8. Sehl ME, Sinsheimer JS, Zhou H and Lange KL. Differential destruction of stem cells: Implications for targeted cancer stem cell therapy. Cancer Res 69: 9481-9489, 2009
9. Malhotra GK, Zhao X, Band H and Band V. Shared signaling pathways in normal and breast cancer stem cells. J Carcinog 10: 38, 2011
10. Harrison H, Farnie G, Howell SJ, Rock RE, Stylianou S, Brennan KR, Bundred NJ and Clarke RB. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res 70: 709-718, 2010
11. Farnie G and Clarke RB. Mammary stem cells and breast cancer-role of Notch signalling. Stem Cell Rev 3: 169-175, 2007
12. Czerwinska P and Kaminska B. Regulation of breast cancer stem cell features. Contemp Oncol (Pozn) 19A: A7-A15, 2015
13. Zhao C, Chen A, Jamieson CH, Fereshteh M, Abrahamsson A, Blum J, Kwon HY, Kim J, Chute JP, Rizzieri D, et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 458: 776-779, 2009
14. Tomasetti C and Vogelstein B. Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science 347: 78-81, 2015
15. Venugopal C, Hallett R, Vora P, Manoranjan B, Mahendram S, Qazi MA, McFarlane N, Subapanditha M, Nolte SM, Singh M, et al. Pyrvinium targets CD133 in human glioblastoma brain tumor-initiating cells. Clin Cancer Res 21: 5324-5337 2015
16. Abetov D, Mustapova Z, Saliev T, Bulanin D, Batyrbekov K and Gilman CP. Novel small molecule inhibitors of cancer stem cell signaling pathways. Stem Cell Rev 11: 909-918, 2015
17. Harada Y, Ishii I, Hatake K and Kasahara T. Pyrvinium pamoate inhibits proliferation of myeloma/erythroleukemia cells by suppressing mitochondrial respiratory complex I and STAT3. Cancer Lett 319: 83-88, 2012
18. Wiegering A, Uthe FW, Hüttenrauch M, Mühling B, Linnebacher M, Krummenast F, Germer CT, Thalheimer A and Otto C. The impact of pyrvinium pamoate on colon cancer cell viability. Int J Colorectal Dis 29: 1189-1198, 2014
19. Zhang X, Lou Y, Zheng X, Wang H, Sun J, Dong Q and Han B. Wnt blockers inhibit the proliferation of lung cancer stem cells. Drug Des Devel Ther 9: 2399-2407, 2015
20. Reya T and Clevers H. Wnt signalling in stem cells and cancer. Nature 434: 843-850, 2005
21. Polyak K. Heterogeneity in breast cancer. J Clin Invest 121: 3786-3788, 2011
22. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100: 8418-8423, 2003
23. Lorico A and Rappa G. Phenotypic heterogeneity of breast cancer stem cells. J Oncol 2011: 135039, 2011
24. Wang A, Chen L, Li C and Zhu Y. Heterogeneity in cancer stem cells. Cancer Lett 357: 63-68, 2015
25. Chen J, Li Y, Yu TS, McKay RM, Burns DK, Kernie SG and Parada LF A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488: 522-526, 2012
26. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756-760, 2006
27. Liu Y, Nenutil R, Appleyard MV, Murray K, Boylan M, Thompson AM and Coates PJ. Lack of correlation of stem cell markers in breast cancer stem cells. Br J Cancer 110: 2063-2071, 2014
28. Bozkulak EC and Weinmaster G. Selective use of ADAM10 and ADAM17 in activation of Notch1 signaling. Mol Cell Biol 29: 5679-5695, 2009
29. Appleyard MV, Murray KE, Coates PJ, Wullschleger S, Bray SE, Kernohan NM, Fleming S, Alessi DR and Thompson AM. Phenformin as prophylaxis and therapy in breast cancer xenografts. Br J Cancer 106: 1117-1122, 2012
30. Livak KJ and Schmittgen TD. Analysis of relative gene expression data using real-Time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001
31. Reynolds BA and Weiss S. Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 255: 1707-1710, 1992
32. Lu S and Labhasetwar V. Drug resistant breast cancer cell line displays cancer stem cell phenotype and responds sensitively to epigenetic drug SAHA. Drug Deliv Transl Res 3: 183-194, 2013
33. Lombardo Y, de Giorgio A, Coombes CR, Stebbing J and Castellano L. Mammosphere formation assay from human breast cancer tissues and cell lines. J Vis Exp: Mar 22, 2015 (Epub ahead of print). doi: 10.3791/52671
34. Hwang-Verslues WW, Lee WH and Lee EY. Biomarkers to target heterogeneous breast cancer stem cells. J Mol Biomark Diagn (Suppl 8): 6, 2012
35. Luo M, Brooks M and Wicha MS. Epithelial-mesenchymal plasticity of breast cancer stem cells: Implications for metastasis and therapeutic resistance. Curr Pharm Des 21: 1301-1310, 2015
36. Li B, Fei DL, Flaveny CA, Dahmane N, Baubet V, Wang Z, Bai F, Pei XH, Rodriguez-Blanco J, Hang B, et al. Pyrvinium attenuates Hedgehog signaling downstream of smoothened. Cancer Res 74: 4811-4821, 2014
37. Bourguignon LY, Wong G, Earle C and Chen L. Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog promotes miR-302 expression leading to self-renewal, clonal formation and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma. J Biol Chem 287: 32800-32824, 2012
38. Peifer M and Polakis P. Wnt signaling in oncogenesis and embryogenesis-A look outside the nucleus. Science 287: 1606-1609, 2000
39. Anastas JN and Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 13: 11-26, 2013
40. Dihlmann S and von Knebel Doeberitz M. Wnt/beta-cateninpathway as a molecular target for future anti-cancer therapeutics. Int J Cancer 113: 515-524, 2005
41. Deng L, Lei Y, Liu R, Li J, Yuan K, Li Y, Chen Y, Liu Y, Lu Y, Edwards CK III, et al. Pyrvinium targets autophagy addiction to promote cancer cell death. Cell Death Dis 4: e614, 2013
42. Gangopadhyay S, Nandy A, Hor P and Mukhopadhyay A. Breast cancer stem cells: A novel therapeutic target. Clin Breast Cancer 13: 7-15, 2013
43. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X and Perou CM. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 12: R68, 2010
44. Asiedu MK, Ingle JN, Behrens MD, Radisky DC and Knutson KL. TGFbeta/TNF(alpha)-mediated epithelial-mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype. Cancer Res 71: 4707-4719, 2011
45. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 106: 13820-13825, 2009
46. Xu W, Lacerda L, Debeb BG, Atkinson RL, Solley TN, Li L, Orton D, McMurray JS, Hang BI, Lee E, et al. The antihelmintic drug pyrvinium pamoate targets aggressive breast cancer. PLoS One 8: e71508, 2013
47. Swanton C, Burrell RA and Futreal PA. Breast cancer genome heterogeneity: A challenge to personalised medicine? Breast Cancer Res 13: 104, 2011
48. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and apredictor of poor clinical outcome. Cell Stem Cell 1: 555-567, 2007
49. de Beça FF, Caetano P, Gerhard R, Alvarenga CA, Gomes M, Paredes J and Schmitt F. Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types. J Clin Pathol 66: 187-191, 2013
50. Bill R and Christofori G. The relevance of EMT in breast cancer metastasis: Correlation or causality? FEBS Lett 589: 1577-1587, 2015
51. Thorne CA, Hanson AJ, Schneider J, Tahinci E, Orton D, Cselenyi CS, Jernigan KK, Meyers KC, Hang BI, Waterson AG, et al. Small-molecule inhibition of Wnt signaling through activation of casein kinase 1α. Nat Chem Biol 6: 829-836, 2010
52. Saraswati S, Alfaro MP, Thorne CA, Atkinson J, Lee E and Young PP. Pyrvinium, apotent small molecule Wnt inhibitor, promotes wound repair and post-MI cardiac remodeling. PLoS One 5: e15521, 2010
53. Venerando A, Girardi C, Ruzzene M and Pinna LA. Pyrvinium pamoate does not activate protein kinase CK1, but promotes Akt/PKB down-regulation and GSK3 activation. Biochem J 452: 131-137, 2013
54. Song L, Li ZY, Liu WP and Zhao MR. Crosstalk between Wnt/β-catenin and Hedgehog/Gli signaling pathways in colon cancer and implications for therapy. Cancer Biol Ther 16: 1-7, 2015
55. Yanai K, Nakamura M, Akiyoshi T, Nagai S, Wada J, Koga K, Noshiro H, Nagai E, Tsuneyoshi M, Tanaka M, et al. Crosstalk of hedgehog and Wnt pathways in gastric cancer. Cancer Lett 263: 145-156, 2008
56. Smith TC, Kinkel AW, Gryczko CM and Goulet JR. Absorption of pyrvinium pamoate. Clin Pharmacol Ther 19: 802-806, 1976
57. Bartucci M, Dattilo R, Moriconi C, Pagliuca A, Mottolese M, Federici G, Benedetto AD, Todaro M, Stassi G, Sperati F, et al. TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells. Oncogene 34: 681-690, 2015